Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 11
Submit an article Journal homepage
279
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy

Neel K. GuptaDivision of Hematology/Oncology, University of California, San Francisco, CA, USA; View further author information
,
Chia-Ching WangDivision of Hematology/Oncology, University of California, San Francisco, CA, USA; ;Zuckerberg San Francisco General Hospital, San Francisco, CA, USA; View further author information
,
Gabriel N. MannisDivision of Hematology/Oncology, University of California, San Francisco, CA, USA; View further author information
,
John-Paul J. YuDepartment of Radiology, University of California, San Francisco, CA, USA; View further author information
&
James L. RubensteinDivision of Hematology/Oncology, University of California, San Francisco, CA, USA; ;Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USACorrespondence[email protected]
View further author information
Pages 2748-2751 | Received 31 Dec 2016, Accepted 12 Mar 2017, Published online: 10 Apr 2017

References

  • Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998;16:859–863.
  • Jacomet C, Girard PM, Lebrette MG, et al. Intravenous methotrexate for primary central nervous system non-Hodgkin’s lymphoma in AIDS. AIDS. 1997;11:1725–1730.
  • Rubenstein JL, Treseler PA, Stewart PJ. Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol. 2011;29:e595–e597.
  • Cox MC, Mannino G, Lionetto L, et al. Lenalidomide for aggressive B-cell lymphoma involving the central nervous system? Am J Hematol. 2011;86:957.
  • Rubenstein JL, Fraser E, Formaker P, et al. Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma. J Clin Oncol 2016;34. (abstr. 7502).
  • Levine AM. Acquired immunodeficiency syndrome-related lymphoma. Blood.1992;80:8–20.
  • Forsyth PA, DeAngelis LM. Biology and management of AIDS-associated primary CNS lymphomas. Hematol Oncol Clin North Am. 1996;10:1125–1134.
  • Raez LE, Patel P, Feun L, et al. Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL). Crit Rev Oncog. 1998;9:199–208.
  • Silverberg MJ, Leyden W, Quesenberry CP Jr, et al. Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. J Gen Intern Med. 2009;24:1065–1072.
  • Saha S, Jacobs EA, Moore RD, et al. Trust in physicians and racial disparities in HIV care. AIDS Patient Care STDs. 2010;24:415–420.
  • Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31:3061–8.
  • Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217–e227.
  • Gupta NK, Nolan A, Omuro A, et al. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro Oncol 2017;19:99–108.
  • Lim H, Kane L, Schwartz JB, et al. Lenalidomide enhancement of human T cell functions in human immunodeficiency virus (HIV)-infected and HIV-negative CD4 T lymphocytopenic patients. Clin Exp Immunol. 2012;169:182–189.
  • Ghesquieres H, Houillier C, Chinot O, et al. Rituximab-lenalidomide (REVRI) in relapse or refractory primary central nervous system (PCNSL) or vitreo retinal lymphoma (PVRL): results of a “proof of concept” phase II study of the French LOC Network 2016 Proc. American Society of Hematology, 58th Annual Meeting and Exposition, San Diego, December 3–6, 2016.
  • Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009;114:4713–4720.
  • Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4 (CRBN.). Br J Haematol. 2014;164:811–821.
  • Lee BN, Gao H, Cohen EN. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer. 2011;117:3999–4008.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.